Lizhao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lizhao Wu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Guoliang Zheng
Department of Pathophysiology, College of Basic Medical Sciences, China Medical University, Shenyang, China; Department of Gastric Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), Shenyang, China
2 shared publicationsTianyi Wu
Department of Pathophysiology, College of Basic Medical Science, China Medical University, No. 77 Puhe Road, Shenyang North New Area District, 110122 Shenyang, Liaoning, People's Republic of China
2 shared publicationsFan Wu
Department of Pathophysiology, College of Basic Medical Sciences, China Medical University, Shenyang, China
1 shared publicationFengli Jiang
Department of Pathophysiology, College of Basic Medical Science, China Medical University, No. 77 Puhe Road, Shenyang North New Area District, 110122 Shenyang, Liaoning, People's Republic of China
1 shared publication- Fengli Jiang
Department of Pathophysiology, College of Basic Medical Sciences, China Medical University, Shenyang, China; Department of Gynecology, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication Guojun Zhang
Department of Pathophysiology, College of Basic Medical Science, China Medical University, No. 77 Puhe Road, Shenyang North New Area District, 110122 Shenyang, Liaoning, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 27 November 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (1) , 108027
E2F1 and E2F7 regulate gastric cancer cell proliferation, respectively, through transcriptional activation and transcriptional repression of MYBL2
- 27 November 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (1) , 108027
Open AccessE2F1 and E2F7 regulate gastric cancer cell proliferation, respectively, through transcriptional activation and transcriptional repression of MYBL2
- Open Access
- 31 May 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
The Role and Clinical Implications of the Retinoblastoma (RB)-E2F Pathway in Gastric Cancer
Gastric cancer is the most common malignant tumor in the digestive tract, with very high morbidity and mortality in developing countries. The pathogenesis of gastric cancer is a complex biological process mediated by abnormal regulation of proto-oncogenes and tumor suppressor genes. Although there have been some in-depth studies on gastric cancer at the molecular level, the specific mechanism has not been fully elucidated. RB family proteins (including RB, p130, and p107) are involved in cell cycle regulation, a process that largely depends on members of theE2Fgene family that encode transcriptional activators and repressors. In gastric cancer, inactivation of the RB-E2F pathway serves as a core transcriptional mechanism that drives cell cycle progression, and is regulated by cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors, p53,Helicobacter pyloriand some other upstream molecules. The E2F proteins are encoded by eight genes (i.e.E2F1toE2F8), each of which may play a specific role in gastric cancer. Interestingly, a single E2F such as E2F1 can activate or repress transcription, and enhance or inhibit cell proliferation, depending on the cell environment. Thus, the function of the E2F transcription factor family is very complex and needs further exploration. Importantly, the presence ofH. pyloriin stomach mucosa may affect the RB and p53 tumor suppressor systems, thereby promoting the occurrence of gastric cancer. This review aims to summarize recent research progress on important roles of the complex RB-E2F signaling network in the development and effective treatment of gastric cancer.
- 31 May 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessThe Role and Clinical Implications of the Retinoblastoma (RB)-E2F Pathway in Gastric Cancer
Gastric cancer is the most common malignant tumor in the digestive tract, with very high morbidity and mortality in developing countries. The pathogenesis of gastric cancer is a complex biological process mediated by abnormal regulation of proto-oncogenes and tumor suppressor genes. Although there have been some in-depth studies on gastric cancer at the molecular level, the specific mechanism has not been fully elucidated. RB family proteins (including RB, p130, and p107) are involved in cell cycle regulation, a process that largely depends on members of theE2Fgene family that encode transcriptional activators and repressors. In gastric cancer, inactivation of the RB-E2F pathway serves as a core transcriptional mechanism that drives cell cycle progression, and is regulated by cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors, p53,Helicobacter pyloriand some other upstream molecules. The E2F proteins are encoded by eight genes (i.e.E2F1toE2F8), each of which may play a specific role in gastric cancer. Interestingly, a single E2F such as E2F1 can activate or repress transcription, and enhance or inhibit cell proliferation, depending on the cell environment. Thus, the function of the E2F transcription factor family is very complex and needs further exploration. Importantly, the presence ofH. pyloriin stomach mucosa may affect the RB and p53 tumor suppressor systems, thereby promoting the occurrence of gastric cancer. This review aims to summarize recent research progress on important roles of the complex RB-E2F signaling network in the development and effective treatment of gastric cancer.